Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone vs Docetaxel in High-risk HER2-negative Breast Cancer
NCT05673629Phase 3Recruiting
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- May 2023
- Primary completion
- Jun 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of utidelone in breast cancer, sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Started May 2023; status: recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05673629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673629.